Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
- 732 Downloads
Monoclonal B cell Lymphocytosis (MBL) or similar terms have been used for decades to describe the presence of light-chain restricted B lymphocytes with uncertain clinical significance, usually having a phenotype consistent with chronic lymphocytic leukemia (CLL). As diagnostic technology improved, ever smaller monoclonal B cell populations were identifiable in the population, and approximately half of people over 90 years old have a minimal (<1 cell/μL) circulating CLL-like B cell population. These minimal CLL-like B cell populations share some molecular characteristics with CLL, but have no clinical significance. In contrast, CLL-like MBL cases detected through hospital investigations are biologically indistinguishable from early stage CLL, but the neoplastic B cell levels are usually stable over time and the risk of progressive disease requiring treatment is much lower than for early stage CLL. However, there is usually partial or complete depletion of normal B cells, with an increased relative risk of severe infection, comparable to early stage CLL, which may impair overall survival.
KeywordsMBL CLL Infection Survival
A. Rawstron: Consultancy work for Biogen Idec.
- 5.Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol. 1990;76:45–57.Google Scholar
- 10.Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press; 2008.Google Scholar
- 18.Mulligan CS, Thomas ME, Mulligan SP. Monoclonal B lymphocytosis: demographics, nature and subclassification in 414 community patients. Leuk Lymphoma. 2011. doi: 10.3109/10428194.2011.598250.
- 19.van Oers MHJ, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010;28:2246–52.PubMedCrossRefGoogle Scholar
- 26.Kern W, et al. Monoclonal B cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol. 2012. doi: 10.1111/j.1365-2141.2011.09010.x.
- 28.HMRN - Incidence. at http://www.hmrn.org/Statistics/Incidence.aspx.
- 34.Bennett FL, Dalal S, Jack AS, Hillmen P, Rawstron AC. Five-year follow-up of monoclonal B cell lymphocytosis (MBL) in individuals with a normal blood count: expansion of the abnormal B cell compartment but no progressive disease. Blood. 2009;114:30–0.Google Scholar
- 36.Shanafelt TD, et al. Survival of patients with clinically identified monoclonal B cell lymphocytosis (MBL) relative to the age- and sex-matched general population. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2011). doi: 10.1038/leu.2011.211.
- 38.Moreira J, et al. Infectious complications among individuals with clinical monoclonal B cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2012. doi: 10.1038/leu.2012.187.
- 50.te Raa GD, van Oers MH, Kater AP. Monoclonal B cell lymphocytosis: recommendations from the Dutch Working Group on CLL for daily practice. Neth J Med. 2012;70:236–41.Google Scholar